万春医药 BYSI 深 沪
等待开盘 04-01 09:30:00 美东时间
1.64
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.64
- 总市值 6743.65万
- 52周最高 3.44
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.10
- 委 比 0.00%
- 总股本 4111.98万
- 历史最高 48.49
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.542
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BeyondSpring publishes IO360 Summit presentation on plinabulin; PD-1/L1 resistance highlighted
BeyondSpring publishes IO360 Summit presentation on plinabulin; PD-1/L1 resistance highlighted BeyondSpring published a presentation titled “Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin.” The presentation was posted as part of the 2026 IO360 Summit materials. Document URL: h
03-26 21:37
BeyondSpring publishes corporate presentation; plinabulin clinical program advances and SEED targeted protein degradation pipeline grows
BeyondSpring publishes corporate presentation; plinabulin clinical program advances and SEED targeted protein degradation pipeline grows BeyondSpring outlined development plans for plinabulin, a small-molecule immune modulator positioned for use with docetaxel in later-line non-small cell lung cance
03-26 18:21
BeyondSpring GAAP EPS of -$0.21
BeyondSpring press release (BYSI): FY GAAP EPS of -$0.21. Cash, cash equivalents, and short-term investments: $12.6 million as of December 31, 2025. More on BeyondSpring Financial information for Beyo...
03-25 20:41
BeyondSpring Q4 EPS $(0.05)
BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.05) per share.
03-25 20:35
BeyondSpring FY2025 operating loss narrows 2.25% to $8.7 million; R&D expenses jump 69.23% to $4.4 million
BeyondSpring FY2025 operating loss narrows 2.25% to $8.7 million; R&D expenses jump 69.23% to $4.4 million Net loss narrowed 2.25% to $8.7 million. R&D expenses jumped 69.23% to $4.4 million on higher drug manufacturing, NSCLC data management, Plinabulin combination research, regulatory consulting,
03-25 20:31
BeyondSpring Files 2025 Annual Report on Form 10-K
BeyondSpring Inc. (NASDAQ: BYSI) announced on March 25, 2026 that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (SEC). The report, containing audited financial statements, is available on the SEC’s website and the Company’s website under “Latest Results” in the Investors section. Shareholders can request a hard copy free of charge. BeyondSpring is a clinica...
03-25 20:30
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Edesa Biotech (NASDAQ:EDSA) shares rose 61.0% to $3.67 during Tuesday'...
03-04 01:05
万春医药股价近一周下跌7%，市值约0.6亿美元
经济观察网 近7天（2026年2月5日至11日），万春医药（BYSI.OQ）股价波动显著，区间累计下跌7.01%，振幅达9.55%。股价波动主要受市场流动性偏低...
02-12 02:46
BeyondSpring Showcases Plinabulin at Immuno-Oncology 360° Conference
BeyondSpring Showcases Plinabulin at Immuno-Oncology 360° Conference BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company specializing in immune-modulating cancer therapies, will participate in the Immuno-Oncology 360° (IO360°) Conference 2026, scheduled for February 10-12, 2
02-09 20:15
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
<p>BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company, announced its participation in the Immuno-Oncology 360° (IO360°) Conference 2026 held in Boston, MA from February 10-12, 2026. Dr. Lan Huang, Co-Founder, Chairman, and CEO, will present on Plinabulin, a differentiated immuno-oncology asset designed to enhance PD-1/PD-L1 blockade. The presentation, titled "Overcoming PD-1/L1 Resistance: Translational Insights with Pli...
02-09 12:15
